Beta Bionics (NASDAQ:BBNX) Now Covered by Analysts at Leerink Partners

Leerink Partners assumed coverage on shares of Beta Bionics (NASDAQ:BBNX) in a research report released on Monday morning, Marketbeat reports. The brokerage issued an outperform rating and a $28.00 target price on the stock.

A number of other equities analysts also recently commented on BBNX. Baird R W upgraded Beta Bionics to a “hold” rating in a report on Thursday, February 20th. Robert W. Baird assumed coverage on shares of Beta Bionics in a research note on Thursday, February 20th. They set a “neutral” rating and a $20.00 price target on the stock. Finally, LADENBURG THALM/SH SH began coverage on shares of Beta Bionics in a report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price target on the stock. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Beta Bionics has a consensus rating of “Moderate Buy” and an average target price of $24.83.

Beta Bionics Stock Performance

Shares of BBNX stock opened at $19.99 on Monday. Beta Bionics has a fifty-two week low of $18.67 and a fifty-two week high of $24.50.

Insider Transactions at Beta Bionics

In other Beta Bionics news, major shareholder Hadley Harbor Aggre Wellington bought 1,000,000 shares of the stock in a transaction on Friday, January 31st. The shares were purchased at an average price of $17.00 per share, with a total value of $17,000,000.00. Following the acquisition, the insider now directly owns 3,901,599 shares of the company’s stock, valued at $66,327,183. This represents a 34.46 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Mike Mensinger purchased 33,350 shares of the company’s stock in a transaction on Friday, January 31st. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $566,950.00. Following the completion of the transaction, the insider now owns 59,019 shares in the company, valued at approximately $1,003,323. This trade represents a 129.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.